We describe a case of a brainstem glioma (BSG) occurred in an adult patient with neurofibromatosis type 1 (NF1) and evaluated by Flourine-18-Fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG-PET/CT). A 32-year-old male patient with NF1 underwent brain magnetic resonance imaging (MRI) for the onset of diplopia, facial paresis and cerebellar signs and symptoms. MRI showed a brainstem lesion compatible with BSG. Biopsy was not performed. 18F-FDG-PET/CT demonstrated intense 18F-FDG uptake in the brainstem lesion, suggesting an aggressive neoplasm. The patient was referred to radiotherapy but he developed rapid disease progression. In this case, 18F-FDG-PET/CT provided useful information about this rare NF1-associated tumor (Figs. 1 and 2).
Subsequently, the patient was referred to radiotherapy, but he developed rapid disease progression and died 3 months later. NF-1 is an autosomal dominant disorder characterized by multiple café-au-lait spots, axillary and inguinal freckling, multiple cutaneous neurofibromas, and iris Lisch nodules [1]. NF-1 is also characterized by low-grade tumors of the central and peripheral nervous system. There is also an increased risk of developing malignant tumors such as malignant peripheral nerve sheath tumors or central nervous system high-grade gliomas [1, 2]. NF1-associated BSGs are less common than NF1-associated optic gliomas (OGs) and seem to represent a particular entity which tend, as a whole, to have a more favorable prognosis and a more indolent course than BSGs in patients without NF1 [3–5]; nevertheless, some NF1-associted BSG may rapidly progress [4]. 18F-FDG-PET/CT has demonstrated to provide useful information to the surveillance of OGs in children with NF1, particularly to identify progressive, symptomatic tumors [6–8]. To the best of our knowledge, there are no data about the usefulness of 18F-FDG-PET/CT in adult patients with NF1-associated BSG. In our case, 18F-FDG-PET/CT has been useful in evaluating this rare NF1-associated tumor.
Acknowledgments
Conflicts of interest
None.
Funding
None.
References
- 1.Jett K, Friedman JM. Clinical and genetic aspects of neurofibromatosis 1. Genet Med. 2010;12:1–11. doi: 10.1097/GIM.0b013e3181bf15e3. [DOI] [PubMed] [Google Scholar]
- 2.Albers AC, Gutmann DH. Gliomas in patients with neurofibromatosis type 1. Expert Rev Neurother. 2009;9:535–9. doi: 10.1586/ern.09.4. [DOI] [PubMed] [Google Scholar]
- 3.Salmaggi A, Fariselli L, Milanesi I, et al. Natural history and management of brainstem gliomas in adults. A retrospective Italian study. J Neurol. 2008;255:171–7. doi: 10.1007/s00415-008-0589-0. [DOI] [PubMed] [Google Scholar]
- 4.Laigle-Donadey F, Doz F, Delattre JY. Brainstem gliomas in children and adults. Curr Opin Oncol. 2008;20:662–7. doi: 10.1097/CCO.0b013e32831186e0. [DOI] [PubMed] [Google Scholar]
- 5.Ullrich NJ, Raja AI, Irons MB, et al. Brainstem lesions in neurofibromatosis type 1. Neurosurgery. 2007;61:762–6. doi: 10.1227/01.NEU.0000298904.63635.2D. [DOI] [PubMed] [Google Scholar]
- 6.Moharir M, London K, Howman-Giles R, et al. Utility of positron emission tomography for tumour surveillance in children with neurofibromatosis type 1. Eur J Nucl Med Mol Imaging. 2010;37:1309–17. doi: 10.1007/s00259-010-1386-4. [DOI] [PubMed] [Google Scholar]
- 7.Roselli F, Pisciotta NM, Aniello MS, et al. Brain F-18 Fluorocholine PET/CT for the assessment of optic pathway glioma in neurofibromatosis-1. Clin Nucl Med. 2010;35:838–9. doi: 10.1097/RLU.0b013e3181ef0b45. [DOI] [PubMed] [Google Scholar]
- 8.Treglia G, Taralli S, Bertagna F, et al. Usefulness of whole-body fluorine-18-fluorodeoxyglucose positron emission tomography in patients with neurofibromatosis type 1: a systematic review. Radiol Res Pract. 2012;2012:431029. doi: 10.1155/2012/431029. [DOI] [PMC free article] [PubMed] [Google Scholar]